BIBLIOGRAPHY \l 1045 1.
Ries LAG,
Harkins D,
Krapcho M,
et al. SEER Cancer Statistics Review,
1975-2003.
Bethesda,
Md: National Cancer Institute. 2006.
2.
Alarcon,
Pedro A de i Arceci,
Chief Editor: Robert J. Pediatric Hodgkin Lymphoma.
http://emedicine.medscape.com. [Online] 30 04 2015.
http://emedicine.medscape.com/article/987101-overview#a5..
3.
Institute,
National Cancer. PDQ® Childhood Hodgkin Lymphoma Treatment.
Bethesda,
MD: National Cancer Institute.
. [Online] 03 02 2016.
http://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq..
4.
van Nimwegen FA,
Schaapveld M,
Janus CP,
et al.:. Cardiovascular disease after Hodgkin lymphoma treatment: 40-year disease risk.
JAMA Intern Med. 2015,
Tom 175 (6),
1007-17.
5.
Chemaitilly W,
Mertens AC,
Mitby P,
et al.:. Acute ovarian failure in the childhood cancer survivor study.
J Clin Endocrinol Metab. 2006,
Tom 91(5),
1723-8.
6.
Constine L.S,
Scott Gamis A.,
Gross T.G et al. PDQ® Childhood Hodgkin Lymphoma Treatment.
[Online] 31 03 2016.
http://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq.
7.
Mauz-Körholz C,
Hasenclever D,
Dörffel et al. Procarbazine-free OEPA-COPDAC chemotherapy in boys and standard OPPA-COPP in girls have comparable effectiveness in pediatric Hodgkin's lymphoma: the GPOH-HD-2002 study.
J Clin Oncol. 28(23),
2010,
3680-6.
8.
Maraldo MV,
Brodin NP,
Aznar MC,
et al. Estimated risk of cardiovascular disease and secondary cancers with modern highly conformal radiotherapy for early-stage mediastinal Hodgkin lymphoma.
Ann Oncol. 2013,
Tom 24(8),
2113-2118.
9.
Raemaekers JM,
Andre MP,
Federico M,
et al. Omitting radiotherapy in early positron emission tomography-negative stage I/II Hodgkin lymphoma is associated with an increased risk of early relapse: Clinical results of the preplanned interim analysis of the randomized EORTC/LYSA/FIL H10 trial.
J Clin Oncol. 2014,
Tom 2014;32(12),
1188-1194.
10.
Specht L,
Yahalom J,
Illidge T,
et al. Modern radiation therapy for Hodgkin lymphoma: field and dose guidelines from the International Lymphoma Radiation Oncology Group (ILROG).
Int J Radiat Oncol Biol Phys . 2014,
Tom 89,
854-862.
11.
Group,
EuroNet-Paediatric Hodgkin’s Lymphoma. First international Inter-Group Study for classical Hodgkin’s Lymphoma in Children and Adolescents EuroNet-PHL-C1.
[Online] 10 09 2007.
https://www.google.pl/url?sa=t&rct=j&q=&esrc=s&source=web&cd=8&ved=0ahUKEwiA0LGm79LLAhXGC5oKHWqVBroQFghbMAc&url=http%3A%2F%2Fwww.lymphome.de%2FGruppen%2FGPOH-HD%2FProtokolle%2FEuroNet-PHL-C1_und_R1%2FSynopsis.pdf&usg=AFQjCNGUM9xLizYqsKgwbCar_UYzDOedFA.
12.
—.
EuroNet-PHL-Interim-Treatment-Guidelines-2012-12-3v0-2.pdf.
[Online] 30 01 2013.
https://www.skion.nl/workspace/uploads/EuroNet-PHL-Interim-Treatment-Guidelines-2012-12-3v0-2.pdf..
13.
Barrington SF,
Mikhaeel NG,
Kostakoglu L et al. Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group.
J Clin Oncol. 2014,
Tom 32(27),
3048-58.
14.
US EPA National Center for Environmental Assessment.
.
SEER cancer statistics review,
1975-2005. 2009.
15.
Berg,
J.
W. The significance of axillary node levels in the study of breast carcinoma.
Cancer . 1955,
Tom 8,
776–778.
16.
Som PM,
Curtin HD,
Mancuso AA. Imaging-based nodal classification for evaluation of neck metastatic adenopathy.
AJR Am J Roentgenol. 2000,
Tom 174 (3),
837-44.
17.
El-Sherief,
A.
H.,
Lau,
C.
T.,
Wu,
C.
C.
et al. International association for the study of lung cancer (IASLC) lymph node map: radiologic review with CT illustration.
RadioGraphics. 2014,
Tom 34(6),
1680-1691.
18.
Papathanassiou D,
Becker S,
Amir R,
et al. Respiratory motion artefact in the liver dome on FDG PET/CT: comparison of attenuation correction with CT and a caesium external source.
Eur J Nucl Med Mol Imaging . 2005,
Tom 32(12),
1422-1428.
19.
Pettinato C,
Nanni C,
Farsad M,
et al. Artefacts of PET/CT images.
Biomedical Imaging and Intervention Journal. 2006,
Tom 2(4):e60.
20.
Hanley J.A.,
Hajian-Tilaki H.O. Sampling Variability of Nonparametric Estimates of the Areas under the Reciver Operating Characteristic Curves: An Update.
Academic Radiology. 1997,
Tom 4,
49-58.
21.
Mauz-Körholz C,
Metzger ML,
Kelly KM et al. Pediatric Hodgkin Lymphoma.
J Clin Oncol. 2015,
Tom 33,
2975-85.
22.
Sklar C,
Whitton J,
Mertens A,
et al.:. Abnormalities of the thyroid in survivors of Hodgkin's disease: data from the Childhood Cancer Survivor Study.
J Clin Endocrinol Metab. 2000,
Tom 85(9),
3227-32.
23.
Bhatia S,
Yasui Y,
Robison LL,
et al.:. High risk of subsequent neoplasms continues with extended follow-up of childhood Hodgkin's disease: report from the Late Effects Study Group.
J Clin Oncol . 2003,
Tom 21(23),
4386-94.
24.
Ng AK,
Bernardo MV,
Weller E,
et al.:. Second malignancy after Hodgkin disease treated with radiation therapy with or without chemotherapy: long-term risks and risk factors.
.
Blood . 2002,
Tom 100(6),
1989-96.
25.
Friedman DL,
Chen L,
Wolden S,
et al.:. Dose-intensive response-based chemotherapy and radiation therapy for children and adolescents with newly diagnosed intermediate-risk hodgkin lymphoma: a report from the Children's Oncology Group Study AHOD0031.
.
J Clin Oncol . 32 (32),
2014,
3651-8.
26.
Yeh JM,
Diller L. Pediatric Hodgkin lymphoma: trade-offs between short- and long-term mortality risks.
Blood. 2012,
Tom 120(11),
2195-202.
27.
Schaefer NG,
Taverna C,
Strobel K et al. Hodgkin disease: diagnostic value of FDG PET/CT after first-line therapy--is biopsy of FDG-avid lesions still needed? Radiology. 244(1),
2007,
257-62.
28.
G Jerusalem,
Y Beguin,
MF Fassotte et al. Whole-body positron emission tomography using 18F-fluorodeoxyglucose compared to standard procedures for staging patients with Hodgkin's disease.
Haematologica. 2001,
Tom 86,
266-273.
29.
Schaefer NG,
Hany TF,
Taverna C et al. Non-Hodgkin lymphoma and Hodgkin disease: coregistered FDG PET and CT at staging and restaging--do we need contrast-enhanced CT? Radiology. 2004,
Tom 232(3),
823-9.
30.
Tan BB,
Flaherty KR,
Kazerooni EA,
et al. The solitary pulmonary nodule.
Chest. 2003,
Tom 123,
89S-96S.
31.
Gould MK,
Maclean CC,
Kuschner WG,
et al. Accuracy of positron emission tomography for diagnosis of pulmonary nodules and mass lesions: a meta-analysis.
JAMA. 2001,
Tom 285,
914-924 .
32.
Ost D,
Fein AM,
Feinsilver SH. Clinical practice.
The solitary pulmonary nodule.
N Engl J Med. 2003,
Tom 348,
2535-2542 .
33.
Centkowski P,
Sawczuk-Chabin J,
Prochorec M et al. Hodgkin's lymphoma and tuberculosis coexistence in cervical lymph nodes.
Leuk Lymphoma. 2005,
Tom 46(3):,
471-5.
34.
Follows G.
A.,
Ardeshna K.
M.,
Barrington S.
F.
et al. Guidelines for the first line management of classical Hodgkin lymphoma.
British journal of haematology. 2014,
Tom 166(1),
34-49.
35.
Dillman J.
R.,
Strouse P.
J.,
Ellis J.
H.
et al. Incidence and severity of acute allergic-like reactions to iv nonionic iodinated contrast material in children.
American Journal of Roentgenology. 2007,
Tom 188(6),
1643-1647.
36.
al.,
Zo’o Martin et. Renal Safety in Pediatric Imaging: Randomized,
Double-Blind Phase IV Clinical Trial of Iobitridol 300 versus Iodixanol 270 in Multidetector CT.
Pediatric Radiology. 2011,
Tom 41.11 (2011),
1393–1400.
37.
Amato E.,
Salamone I.,
Naso S.
et al. Can contrast media increase organ doses in CT examinations? A clinical study.
American Journal of Roentgenology. 2013,
Tom 200(6),
1288-1293.
38.
Birnbaum B.
A.,
Hindman N.,
Lee J.
et al. Renal Cyst Pseudoenhancement: Influence of Multidetector CT Reconstruction Algorithm and Scanner Type in Phantom Model 1.
Radiology. 2007.
39.
+ [Boas F.
E.,
Fleischmann D. + [Boas,
F.
E.
& Fleischmann,
D.
CT artifacts: causes and reduction techniques.
http://dx.doi.org/10.2217/iim.12.13 4. 2012,
229–240.
40.
Morrill SM,
Langer ML,
Lane RG et al. Tissue heterogeneity effects in treatment plan optimization.
Int J Radiat Oncol Biol Phys.
. 1994,
Tom 30,
699-706.
41.
Burridge N.
A.,
Rowbottom C.
G.,
Bur P.
A. Effect of contrast enhanced CT scans on heterogeneity corrected dose computations in the lung.
.
Journal of Applied Clinical Medical Physics. 2006,
Tom 7(4).
42.
S.A.,
Elmore. Histopathology of the Lymph Nodes.
Toxicol Pathol. 34(5),
2006,
425–454.
43.
Pombo F.,
Rodriguez E.,
Caruncho MV.,
et al. CT attenuation values and enhancing characteristics of thoracoabdominal lymphomatous adenopathies.
J Comput Assist Tomogr. 1994,
Tom 18(1),
59-62.
44.
Flechsig P.,
Choyke P.,
Kratochwil C.
et al. Increased x-ray attenuation in malignant vs.
benign mediastinal nodes in an orthotopic model of lung cancer.
Diagn Interv Radiol. 2015,
Tom 22(1),
35-9.
45.
Yoon Kyung K.,
Kyung Soo L,
Byung-Tae K.
et al. Mediastinal Nodal Staging of Nonsmall Cell Lung Cancer Using Integrated 18F-FDG PET/CT in a Tuberculosis-Endemic CountryDiagnostic Efficacy in 674 Patients.
CANCER. 2007,
Tom 109(6),
1068-77.
46.
Urata M.,
Kijima Y.,
Hirata M.
et al. Computed tomography Hounsfield units can predict breast cancer metastasis to axillary lymph nodes.
BMC Cancer. 2014,
Tom 14,
730.
47.
Kim S.A.,
Lee K.N.,
Kang E.J.,
et al. Hounsfield units upon PET/CT are useful in evaluating metastatic regional lymph nodes in patients with oesophageal squamous cell carcinoma.
Br J Radiol. 2012,
Tom 85(10123),
606-12.
48.
Tan BB,
Flaherty KR,
Kazerooni EA,
et al. The solitary pulmonary nodule.
Chest. 2003,
Tom 123,
89S-96S .
49.
Gould MK,
Maclean CC,
Kuschner WG,
et al. Accuracy of positron emission tomography for diagnosis of pulmonary nodules and mass lesions: a meta-analysis.
JAMA. 2001,
Tom 285,
914-924.
Normal 0 21 false false false PL X-NONE X-NONE
50.
Bui,
A.,
Taira,
R.
K. Medical imaging informatics. brak miejsca : Springer Science & Business Media,
2010.